Harmony Biosciences Holdings, Inc. Stock Price, News & Analysis

Harmony Biosciences Holdings (Nasdaq: HRMY) announced participation in three upcoming investor conferences. President and CEO John Jacobs will host fireside chats at:

• Jefferies Healthcare Conference on June 2, 2021, at 2:30 PM ET
• Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 3:50 PM ET
• Raymond James Human Health Innovation Conference on June 21, 2021, at 3:20 PM ET

Live webcasts will be available on Harmony's investor page. The company focuses on innovative therapies for rare neurological disorders.

Harmony Biosciences announced the appointment of John C. Jacobs as a member of the Life Sciences Pennsylvania's Board of Directors, effective May 6, 2021. Under his leadership, Harmony has focused on innovative therapies for rare neurological disorders. Jacobs brings almost three decades of experience in the pharmaceutical sector, enhancing his ability to support local patient communities and advance the life sciences industry in Pennsylvania. His appointment underscores Harmony’s commitment to leadership within the sector and aims to bolster the company’s influence and initiatives in the region.

Harmony Biosciences Holdings, based in Plymouth Meeting, PA, announced a company update presentation at the Oppenheimer Rare and Orphan Disease Summit on May 21, 2021. President and CEO John C. Jacobs and Chief Medical Officer Dr. Jeffrey Dayno will host investor meetings during the event. The presentation will be accessible via a webcast on Harmony's investor page. The company focuses on developing therapies for rare neurological disorders with unmet medical needs.

Harmony Biosciences (HRMY) reported a strong start to 2021, achieving a net product revenue of $59.7 million for Q1, compared to $19.8 million in Q1 2020. This marks profitability with a net income of $7.4 million, a significant turnaround from a net loss of $38.6 million last year. The growth is attributed to increased demand for WAKIX, now approved for both excessive daytime sleepiness and cataplexy in narcolepsy. Cash reserves stand at $141.2 million and clinical trials for other indications are ongoing, positioning the company for future development.

Harmony Biosciences (Nasdaq: HRMY) announced that data from its WAKIX® (pitolisant) clinical development program will be presented at the 2021 American Psychiatric Association Annual Meeting from May 1-3. WAKIX is approved for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy. Presentations will cover the efficacy and safety of WAKIX in narcolepsy patients, including data from pivotal clinical trials. Harmony aims to enhance understanding of narcolepsy's impact on mental health, as noted by Chief Medical Officer Jeffrey Dayno.

Harmony Biosciences (Nasdaq: HRMY) announced that clinical results for WAKIX® (pitolisant) will be presented at the 2021 American Academy of Neurology Annual Meeting from April 17-22. These include two analyses: one on the time-to-onset of clinical response during treatment and another on the cardiovascular safety profile of WAKIX in narcolepsy patients. WAKIX, approved for treating excessive daytime sleepiness, has been available since Q4 2019. The meeting presentations aim to enhance understanding of WAKIX's efficacy and safety for patients with narcolepsy.

Harmony Biosciences Holdings, Inc. (HRMY) has launched the Progress at the Heart grant program aimed at addressing disparities in access to healthcare for patients with sleep disorders, especially within underrepresented communities. Announced on April 7, 2021, the initiative will allocate up to $125,000 in grants by September 2021, focusing on community- and education-based solutions. Two application rounds are open from April 7 to May 31 and June 1 to August 20. This program underscores Harmony's commitment to enhancing equality of care for rare disease and sleep disorder patients.

Harmony Biosciences (HRMY) announced total revenue of $160 million for 2020, with $56 million generated in Q4. The FDA expanded the approval of WAKIX for treating cataplexy in adults with narcolepsy. Harmony reported a net loss of $36.9 million for the year but achieved significant growth in net product revenue, increasing from $6 million in 2019. Cash reserves rose to $228.6 million compared to $24.5 million in the prior year. The company is advancing clinical trials, including a Phase 2 trial for Prader-Willi Syndrome.

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) published a white paper following its December 2020 Summit on Sleep Disruption, focusing on the challenges of excessive daytime sleepiness (EDS) in patients with rare neurological disorders. The summit gathered patients, caregivers, and advocacy leaders to discuss EDS's impact. Key findings highlight issues like increased anxiety, reduced cognitive abilities, and challenges in diagnosis and treatment. The company aims to raise awareness of EDS in rare diseases, with ongoing collaborations with advocacy groups to share insights.